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Abstract The treatment of patients with multiple myeloma
usually includes many drugs including thalidomide, lenali-
domide and bortezomib. Lovastatin and other inhibitors of
HMG-CoA reductase demonstrated to exhibit antineoplas-
matic and proapoptotic properties in numerous in vitro
studies involving myeloma cell lines. We treated 91 patients
with relapsed or refractory multiple myeloma with thalid-
omide, dexamethasone and lovastatin (TDL group, 49
patients) or thalidomide and dexamethasone (TD group,
42 patients). A clinical response defined of at least 50%
reduction of monoclonal band has been observed in 32% of
TD patients and 44% of TDL patients. Prolongation of
overall survival and progression-free survival in the TDL
group as compared with the TD group has been docu-
mented. The TDL regimen was safe and well tolerated. The
incidence of side effects was comparable in both groups.
Plasma cells have been cultured in vitro with thalidomide
and lovastatin to assess the impact of both drugs on the
apoptosis rate of plasma cells. In vitro experiments revealed
that the combination of thalidomide and lovastatin induced
higher apoptosis rate than apoptosis induced by each drug
alone. Our results suggest that the addition of lovastatin to
the TD regimen may improve the response rate in patients
with relapsed or refractory myeloma.
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Introduction
Multiple myeloma (MM) is a malignant disorder charac-
terised by an uncontrolled clonal proliferation of malignant
plasma cells which produce a monoclonal paraprotein. MM
is the second most common haematological malignancy
with an annual incidence of approximately 30,000 patients
in Europe, resulting in 16,000 deaths yearly. Several
combination chemotherapy regimens have been imple-
mented, but still median survival was not significantly
affected and remains short—3–4 years for older patients
and approaching 6–6.5 years for younger patients eligible
for high-dose therapy and autologous transplantation [1–3].
M. Hus (*) :N. Grzasko :M. Adamczyk-Cioch :D. Jawniak :
W. Legiec :M. Morawska : J. Kozinska :A. Dmoszynska
Department of Haematology and Bone Marrow Transplantation,
Medical University of Lublin,
Staszica 11,
20-081 Lublin, Poland
e-mail: markhus@o2.pl
M. Szostek
Department of Haematology, Collegium Medicum,
Jagiellonian University of Cracow,
Cracow, Poland
A. Pluta
Department of Haematology,
Podkarpackie Oncology Center Hospital,
Brzozow, Poland
G. Helbig
Department of Haematology, Silesian Medical University,
Katowice, Poland
D. Woszczyk
Department of Haematology, State Hospital,
Opole, Poland
P. Waciński
Department of Cardiology, Medical University of Lublin,
Lublin, Poland
Ann Hematol (2011) 90:1161–1166
DOI 10.1007/s00277-011-1276-2
MM remains an incurable disease despite the implementa-
tion of new agents: thalidomide (THAL), lenalidomide and
bortezomib [4, 5]. Monotherapy with thalidomide
approaches a 25% response rate in refractory and de novo
treated myeloma patients. Dexamethasone (DEX) inclusive
multidrug regimens result in 40–55% response rate of
patients in relapse or resistant to either agent [6]. Lovastatin
(LOV) and other inhibitors of HMG-CoA reductase (the
rate-limiting enzyme of the mevalonate pathway) have been
demonstrated to exhibit antineoplasmatic and proapoptotic
properties in numerous in vitro studies involving myeloma
cell lines [7–9]. The downstream molecular mechanism of
statins inducing apoptosis in tumour cells involves the
depletion of geranylgerany, an end product of the mevalo-
nate pathway and a substrate used in protein isoprenylation
[10, 11]. LOV and other statins effectively suppressed the
production of vascular endothelial growth factor by tumour
cells harbouring RAS mutations in vitro [12].
This observation stimulated us to administer LOV in
combination with THAL and DEX in refractory multiple
myeloma patients. The results of our experience with
THAL and LOV therapy in patients with relapsed or
refractory MM have been reported.
Design and methods
Ninety-one patients with relapsed or refractory multiple
myeloma were enrolled at four Polish haematology centres
and randomly assigned to receive THAL, DEX and LOV
(TDL group) or THAL and DEX (TD group). Patients'
characteristics prior to the start of treatment are summarised
in Table 1. We compared TDL and TD groups in terms of:
age, disease stage according to the International Staging
System (ISS), renal function, blood morphology, bone
marrow plasma cells number, as well as serum total protein,
monoclonal band, albumins, beta-2-microglobulin, C-
reactive protein and LDH level. Chromosomal studies have
not been performed in the majority of patients; therefore,
these results will not be analysed. We did not observe
statistically significant differences between compared
parameters in analysed patient groups except serum urea
level, which was lower in TDL than in the TD group
(median 38.7 mg/day versus 48.3 mg/dL, p=0.04),
although serum creatinine concentrations were not signifi-
cantly different.
Treatment groups consisted of adult (>18 years) patients
with relapsed or refractory myeloma. Measurable disease
has been defined as a serum monoclonal immunoglobulin
concentration of at least 10 g/L for IgG or 5 g/L for IgA in
patients with relapsed or refractory myeloma, or urinary
light chains excretion of at least 200 mg per 24 h. Patients
with nonsecretory MM had respective measurable disease
activity assessment (immunophenotyping, MRI). Beta-2
microglobulin and albumin studies have been performed
in all patients. The ISS protocol investigation staging
system has been implemented. All patients had relapsed
following previous one to two lines of chemotherapy or
were resistant to treatment with at least one to two lines of
chemotherapy. Eligibility criteria included WHO perfor-
mance status of 0–2, serum ASPATor ALAT no higher than
two times the upper limit of normal, serum creatinine level
less than 2 mg/dL, platelet count of at least 50 G/L and
absolute neutrophil count of at least to 1.0 G/L. Exclusion
criteria included clinically relevant infection (e.g. hepatitis
B or C), serious comorbidities or prior malignancy. Patients
consented to use mechanical contraception during the study
period. Only patients with a negative urine pregnancy test
have been included in the study. All patients gave written
informed consent before entering the study. The study has
been performed according to the Declaration of Helsinki,
Table 1 Patients' characteristics
TLD (n=49) TD (n=42)
Age 59.3±7.7 62.4±8.9
Sex Female, 25 Female, 22
Male, 24 Male, 20
Patients resistant to chemotherapy 5 4
Relapsed patients 44 38
Chemotherapy lines/courses (median) 2/8 2/9
Type of myeloma IgG 28 IgG 24
IgA, 15 IgA, 12
Light chain
disease, 2
Light chain
disease, 4
Nonsecretory,
2
Nonsecretory,
1
Solitare, 2 Solitare, 1
Light chain Kappa, 38 Kappa, 32
Lambda, 11 Lambda, 10
Cytogenetics
Isolated del(17p13) 4 3
Complex abnormalities: t(4;14), del
(17p13), del (13q14)
3 3
Without abnormalities 7 6
No data 35 30
Marrow plasma cells (%) 43.7±27.4 49.2±26.3
CRP (mg/L) 11.4±30.5 9.4±14.2
B2M (mg/L) 3.7±3.6 3.58±3.7
LDH (IU/L) 296.4±160.9 282.6±142.1
Creatinine (mg/dL) 1.0±0.5 1.6±1.8
ISS prognostic index
ISS 1 5 4
ISS 2 38 31
ISS 3 6 7
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under the auspices of protocol approved by the institutional
ethics committee.
Therapeutic protocol
Patients received drugs orally in 28-day cycles. THAL was
given from day 1 to day 28 of each cycle at a dose of
100 mg at bedtime. DEX was administered at a dose of
20 mg daily on days 1–4 of each cycle. LOV was
administered at a dose of 2 mg/kg on days 1–5 and 8–12
and at a dose of 0.5 mg/kg on days 15–28 of each cycle.
TDL regimen was administered to 49 patients and the TD
regimen to 42 patients. Treatment was discontinued in
patients who progressed to TD or TDL and was withheld
for grade 3 or worse non-haematological toxicity, or grade 4
haematological toxicity. Aspirin (75 mg/day) was given as
thromboprophylaxis. All patients received 90 mg intrave-
nous pamidronate monthly. The high dose of cyclophos-
phamide (4 g/m2) with filgrastim was applied as
mobilisation. The conditioning regimen consisted of a high
dose of melphalan—200 mg/m2.
Assessment of response
The response to therapy was assessed after 6 cycles
according to the modified criteria of the European Group
for Blood and Marrow Transplantation. Briefly, a complete
response (CR) was defined by the absence of monoclonal
protein (M-protein) in the serum and urine confirmed by
immunofixation and normal serum free light chain ratio,
which was in turn confirmed by repeated measurements
after 6 weeks. Near-complete response (NCR) was defined
as CR with positive immunofixation test. A partial response
was defined as the reduction of monoclonal protein in
serum by at least 50% and reduction in urine by at least
90%. Progressive disease was defined by an increase of M-
protein in the serum or urine of more than 25%, an increase
in bone marrow plasma cells and new hypercalcemia. The
toxicity of TDL and TD regimens was assessed according
to CTC.
In vitro short-term culture of plasma cells
Mononuclear cells of the patients' bone marrow were
isolated by Ficoll-Hypaque density gradient centrifugation.
The percentage of plasma cells was evaluated by triple
staining (CD138/FITC, CD38/PE and CD45/PC-5) and
analysed by flow cytometry. Isolated cells were cultured in
Roswell Park Memorial Institute 1640 medium and
supplemented with 10% foetal bovine serum and 10 μg/
mL of THAL or 10 μM of LOV, or the combination of both
drugs in a humidified atmosphere of 5% CO2 and 37°C.
LOV in the inactive form was obtained from Merck
Laboratories, USA. It was converted to the active form by
dissolving in ethanol, heating at 50°C in 0.1 M NaOH and
neutralised with HCl. Distilled water was added to a final
concentration of 8 mg/mL. This stock solution was frozen
at −20°C and its 1-μl aliquots were added per millilitre of
cell culture. After 24 and 48 h of incubation, the cells were
washed and stained with annexin V/FITC and propidium
iodide to detect apoptosis. The percentage of apoptotic cells
was determined by flow cytometry analysis on FACSCali-
bur™ using CellQuest™ software (Fig. 1).
Statistical analysis
The survival analysis was performed in patients from TDL
and TD groups who did not receive high-dose therapy with
autologous stem cell transplant (HDT/ASCT) following
TDL or TD regimen (31 TDL and 38 TD patients). This
allowed us to exclude the HDT/ASCT influence on
survival, as the proportion of patients given HDT/ASCT
in both groups was not equal. Overall survival (OS) was
defined as the time from study entry to death or the last date
on which the patient was alive. Progression-free survival
(PFS) was defined as the time from study entry to any event
such as disease progression or death from any cause. The
survival analyses were done by the Kaplan–Meier method.
The influence of independent variables on survival was
tested by proportional Cox hazard regression. Differences
in clinical parameters between the TDL and TD groups
were tested by Mann–Whitney U test. Assessment of the
impact of drugs in cell culture was performed using
Friedman ANOVA test.
The primary objectives of the study were to determine
the durations of PFS and OS in both groups of patients. The
secondary objectives of this study were to determine the
toxicity of thalidomide and dexamethasone in combination
with lovastatin and to demonstrate the possibility of stem
cell harvesting and autologous bone marrow transplant after
treatment with thalidomide, dexamethasone and lovastatin.
Results
Thirty-two percent of TD and 44% of TDL patients
responded to the treatment. NCR and CR were observed
in 5% and 11%, respectively (Table 2). We observed a
significant negative correlation between response and bone
marrow infiltration (p<0.005). The median time to response
was shorter in the TDL group than in the TD group (1.5
versus 3 months, respectively; p=0.001). Short time to 50%
reduction of M-protein was associated with better response.
Among patients who had not been submitted to HDT/
ASCT treatment, patients treated with TDL regimen had
median overall survival of 49 versus 39.5 months in TD
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patients although the difference was not statistically
significant. Figure 2a shows the Kaplan–Meier estimate of
OS in both groups of patients. The evaluation of PFS in
patients without HDT/ASCT showed significant differ-
ences. PFS was significantly shorter in patients treated
with TD regimen (median 16 months) in comparison to
TDL-treated patients (median 33 months, p=0.04849 in
Wilcoxon–Gehan test). Figure 2b presents the Kaplan–
Meier estimate of PFS in both groups of patients.
In 21 (42.8%) TDL and 7 (16.6%) TD patients, successful
stem cell harvest was performed and the median number of
collected CD34+ cells was 8.26×106 per kg in the TDL
group and 6.76×106 per kg in the TD group (p>0.05).
Successful autologous stem cell transplantation was per-
formed in 18 (36.7%) patients of the TDL group and 4
(9.5%) of the TD group. The recovery time for WBC >0.5 g/
l and PLT >20 g/l was comparable in the TDL and TD
groups (p>0.05 for WBC and PLT). The 100-day transplant-
related mortality was 0%.
Toxicity profile
The TDL regimen was well tolerated. We did not observe toxic
death during the treatment. Common side effects such as
somnolence, fatigue and constipation were observed in about
20% of the patients in both the TDL and TD groups. In four
(8.2%) TDL and two (4.8%) TD patients, we diagnosed deep
vein thrombosis. In one patient in the TDL group, grade 4
pulmonary embolism occurred.We observed grade 3–4 sensory
neuropathy in 12 (24.3%) patients in the TDL group and 10
(23.8%) patients in the TD group. Five (10.2%) TDL patients
were observed with a moderate increase of aminotransferases.
No TDL-treated patients were observed with increased
myoglobine and troponine following treatment. In three
(6.1%) TDL and two (4.8%) TD patients, sinus bradycardia
was observed. Neutropenia was noted in four (8.2%) TDL
and four (9.6%) TD patients and thrombocytopenia was
noted in two (4.1%) TDL and two (4.8%) TD patients.
We did not observe any haematological adverse events in
grade 3 or 4 according to CTC. The summary of side
effects in grade 3 or 4 is shown in Table 3.
Fig. 1 a–c Thalidomide (THAL) and lovastatin (LOV) induced higher
apoptosis rate than apoptosis rate induced by each drug alone. The
percentage of early apoptotic cells evaluated after 24 and 48 h of cell
culture was higher in the presence of both THAL and LOV. The
median percentage of early apoptotic cells after 24 h of culture was
4% versus 2% in the presence of THAL and 1.5% in the presence of
LOV. After 48 h of culture, the median values were 28%, 26% and
22%, respectively. At both time points, the differences were
statistically significant (p<0.001 using Friedman ANOVA test)
Table 2 Percentage of responders and non-responders
TLD (n=49) (%) TD (n=42) (%)
Clinical response 44 32
M-protein reduction 50–75% 17 17
>75% 16 10
>90% 11 5
CR (IF) 7 2
No response 56 68
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Discussion
This is the first trial comparing TD with TDL efficacy in
refractory or relapsed patients with MM. There are only a
few publications concerning the activity of LOV in
myeloma and its relation to the regulation of apoptosis in
MM cells [7, 9, 11]. In our study, the assessment of early
apoptotic signals was done in 25 short-term cultures of
plasma cells obtained from patients with relapsed MM.
Detection of apoptosis after 24 and 48 h of incubation
confirmed that LOV has additional influence on the
induction of apoptosis (Fig. 1). Results of in vitro studies
of statins against myeloma cells showed that statins' activity
in the concentration ranged between 1 and 30 μM. We
assumed, therefore, that only high doses of statins could be
beneficial for MM patients. Thibault et al. [13] in a clinical
study assessed the tolerability of LOV administered at a
dose ranging from 2 to 45 mg/kg/day with 7-day courses
given monthly in patients with various types of cancer.
They concluded that the administration of LOVat a dose of
10–25 mg/kg daily for seven consecutive days was well
tolerated by cancer patients. Dmoszynska et al. [14]
administered LOV in a patient with relapsed MM at a daily
dose of 15 mg/kg for ten consecutive days monthly for
three consecutive months with ubiquinone prophylaxis at a
dose of 240 mg daily. They did not report severe adverse
events, including cardiomyolysis. Sondergaard et al. [15],
in a phase 2 trial, used simvastatin in six patients at a daily
dose of 15 mg/kg in 7-day cycles. The study was
prematurely discontinued due to the absence of clinical
response and the presence of adverse events.
In our study, 49 patients in the TDL group received LOV
at a dose of 1 mg/kg (55 to 90 mg daily, median 65 mg
daily) for 5 days and weekly for two consecutive weeks.
Patients received a maintenance dose of 0.5 mg/kg for the
next 2 weeks. We did not observe clinical or biochemical
evidence of significant toxicity. Apathy and muscle weak-
ness were observed in about 15% of the patients both in the
TDL and TD groups. It is not clear whether they have been
related to dexamethasone or lovastatin therapy. Results in
the TDL group showed a significantly higher rate of very
good responses (CR and NCR) and significantly shorter
time to response in comparison to the TD-treated patients.
Comparison between our results and the results reported by
different authors using TD regimen is difficult due to
different doses of THAL and DEX and different therapy
schemes studied. Lilienfeld-Toal et al. [16] conducted a
review of 12 studies evaluating TD regimen in refractory
and relapsed myeloma. Among 451 patients included in all
reviewed studies, the response rate was 46%, six studies
reported a median PFS of 8 months (range 3.9 to 12 months)
Fig. 2 Overall survival (OS) and progression-free survival (PFS) in
both groups of patients including TD or TDL therapy and high-dose
melphalan. a Median OS was longer in patients treated with TDL
regimen than with TD regimen (47.5 versus 36.5 months, p=0.073). b
Median PFS was significantly longer in the TDL group as compared
to the patients treated with TD (28.5 versus 6 months, p=0.0484)
Table 3 Side effects of treatment
CTC TLD (n=49) TD (n=42)
Neuropathy sensory 12 (24.3%) 10 (23.8%)
Fatigue (lethargy, malaise or asthenia) 10 (20.4%) 8 (19.0%)
Constipation 8 (16.3%) 6 (14.3%)
Somnolence/depressed level
of consciousness
5 (10.2%) 4 (9.5%)
Dizziness 4 (8.2%) 4 (9.5%)
Thrombosis/embolism 4 (8.2%) 2 (4.8%)
Oedema 3 (6.1%) 2 (4.8%)
Sick bradycardia 3 (6.1%) 2 (4.8%)
Allergic reaction/hypersensitivity 2 (4.1%) 2 (4.8%)
Nausea 2 (4.1%) 2 (4.8%)
Vomiting 2 (4.1%) 1 (2.4%)
Fever 0 (0.0%) 1 (2.4%)
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and median OS reported by seven studies was 27 months
(range 13 to 38 months). In our study, the response rate was
lower and reached 32% of patients achieving at least partial
response. Such difference may reflect a higher dose of
THAL used in most of the reviewed studies. We used the
daily dose of 100 mg, whereas such a dose was used only
in one study; median starting dose was 200 mg daily and
median target dose was 350 mg daily [16]. Murakami et al.
[17] treated 66 patients with relatively low dose of THAL
and they obtained results comparable to ours. Overall
response rate according to the authors’ criteria was 63.6%,
but only 25.8%of the patients achieved at least partial response
with the reduction ofM-protein level by 50%. Themedian PFS
and OS were longer in our patients (16 and 39.5 months,
respectively) than in the analysis done by Lilienfeld-Toal et al.
[16]. In another study, Palumbo et al. [18] treated 120
patients, administering THAL at a daily dose of 100 mg and
DEX at a daily dose of 40 mg for four consecutive days
monthly. The results of their studies have similar results to
our results. In patients after one line of chemotherapy, the
median PFS was 17 months and the median OS was not
reached, but the probability of survival of 3 years was 60%.
In patients after two or more lines of chemotherapy, the
median PFS and OS were 11 and 19 months, respectively.
Anagnostopoulos et al. [19] reported the median OS of
38 months. Cibeira et al. [20] reported PFS of 15.6 months
and OS of 28.4 months among relapsing MM patients.
In our study, patients treated with TDL regimen had
significantly prolonged survival and overall survival (me-
dian PFS over 33 months and median OS over 49 months).
These results suggest that the addition of LOV to THAL
and DEX is safe and improves the response rate in patients
with relapsed or refractory MM, without hampering
mobilisation efficacy and implementation of high-dose
therapy. A future prospective randomised study is needed
to confirm the value of LOVor other HMG-CoA reductase
inhibitors in the treatment of MM patients.
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